UNSPSC 51241104: Brinzolamide

This classification denotes a carbonic anhydrase inhibitor and anti-glaucoma agent with the molecular formula C12H21N3O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9451Z89515, chemically known as 2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (r)- but generally known as brinzolamide, which bears US NIH Compound Identifier 68844. European Medicines Agency schedules Brinzolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05892MIG.

UNSPSC 51241104 Brinzolamide is a Commodity code covering branded and generic ophthalmic antiglaucoma agents supplied to state and local government health systems, correctional facilities, and public health programs. State and local procurement activity under this code centers on multistate cooperative purchasing agreements that consolidate demand across multiple jurisdictions to secure volume pricing on pharmaceutical products, including brinzolamide and related therapeutics, sourced through licensed wholesalers and distributed to end-user facilities. Issuing bodies include state departments of administration and health, counties, and municipalities participating in multistate purchasing consortia that leverage collective volume to negotiate manufacturer pricing and ensure supply chain compliance with FDA requirements, cGMP certification, and Drug Supply Chain Security Act (DSCSA) obligations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products spanning Minnesota, Oregon, and participating members. The solicitation, due March 26, 2026, requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded pricing effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent), fixed pricing stability (10 percent), EDI capability (5 percent), and compliance with administrative fee and data-format requirements (10 percent combined). Vendors must maintain relationships with at least two of the three wholesalers, certify cGMP and DSCSA compliance, carry commercial general liability insurance of $5 million per occurrence, and accept a 3 percent administrative fee on all contract purchases with performance penalties of $200 to $1,500 per violation for late reporting or missed milestones.